(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Glioma D005910 112 associated lipids
Insulin Resistance D007333 99 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Tashiro M et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. 2012 Med. Mycol. pmid:21954955
Cordeiro RA et al. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. 2013 Med. Mycol. pmid:22712455
Sarazin A et al. In vitro pro- and anti-inflammatory responses to viable Candida albicans yeasts by a murine macrophage cell line. 2010 Med. Mycol. pmid:20438293
Kim SY et al. Inhibition effect of new farnesol derivatives on all-trans-retinoic acid metabolism. 2001 Metab. Clin. Exp. pmid:11699057
Wang C et al. Engineered heterologous FPP synthases-mediated Z,E-FPP synthesis in E. coli. 2013 Metab. Eng. pmid:23608473
Rotblat B et al. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. 2008 Meth. Enzymol. pmid:18374183
Berzat AC et al. Using inhibitors of prenylation to block localization and transforming activity. 2006 Meth. Enzymol. pmid:16757354
Epand RM et al. Lipid-mediated a-factor interactions with artificial membranes. 1995 Meth. Enzymol. pmid:7651149
Deveau A and Hogan DA Linking quorum sensing regulation and biofilm formation by Candida albicans. 2011 Methods Mol. Biol. pmid:21031315
Andres DA et al. Rapid identification of cysteine-linked isoprenyl groups by metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. 1999 Methods Mol. Biol. pmid:10399149
Dudler T and Gelb MH Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. 1999 Methods Mol. Biol. pmid:10399152
Corsini A et al. Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. A useful tool for studying protein prenylation. 1999 Methods Mol. Biol. pmid:10399150
Hisajima T et al. Protective effects of farnesol against oral candidiasis in mice. 2008 Microbiol. Immunol. pmid:18667031
Abe S et al. Suppression of anti-Candida activity of macrophages by a quorum-sensing molecule, farnesol, through induction of oxidative stress. 2009 Microbiol. Immunol. pmid:19493200
Cugini C et al. Candida albicans-produced farnesol stimulates Pseudomonas quinolone signal production in LasR-defective Pseudomonas aeruginosa strains. 2010 Microbiology (Reading, Engl.) pmid:20656785
Machida K et al. Farnesol-induced growth inhibition in Saccharomyces cerevisiae by a cell cycle mechanism. 1999 Microbiology (Reading, Engl.) pmid:10075411
Laffey SF and Butler G Phenotype switching affects biofilm formation by Candida parapsilosis. 2005 Microbiology (Reading, Engl.) pmid:15817776
Gouveia V et al. Di- and sesquiterpenoids from Cystoseira genus: structure, intra-molecular transformations and biological activity. 2013 Mini Rev Med Chem pmid:23621654
Charron G et al. Alkynyl-farnesol reporters for detection of protein S-prenylation in cells. 2011 Mol Biosyst pmid:21107478
Kloog Y and Cox AD RAS inhibitors: potential for cancer therapeutics. 2000 Mol Med Today pmid:11006529
Foster JM et al. Biosynthesis of isoprenoid compounds in Schistosoma mansoni. 1993 Mol. Biochem. Parasitol. pmid:8264731
Agassandian M et al. Calcium-calmodulin kinase I cooperatively regulates nucleocytoplasmic shuttling of CCTα by accessing a nuclear export signal. 2012 Mol. Biol. Cell pmid:22621903
Charette N et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. 2010 Mol. Cancer pmid:20860815
Levy R et al. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. 2010 Mol. Cancer Ther. pmid:20682656
Barkan B et al. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. 2011 Mol. Cancer Ther. pmid:21632464
Goldberg L et al. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. 2008 Mol. Cancer Ther. pmid:19001442
Zundelevich A et al. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). 2007 Mol. Cancer Ther. pmid:17541036
Blum R et al. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. 2006 Mol. Cancer Ther. pmid:16985068
Ura H et al. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. 1998 Mol. Carcinog. pmid:9496909
Stärkel P et al. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. 2012 Mol. Carcinog. pmid:21882255
Léger T et al. The Metacaspase (Mca1p) Restricts O-glycosylation During Farnesol-induced Apoptosis in Candida albicans. 2016 Mol. Cell Proteomics pmid:27125826
Léger T et al. The metacaspase (Mca1p) has a dual role in farnesol-induced apoptosis in Candida albicans. 2015 Mol. Cell Proteomics pmid:25348831
Ferdinandy P et al. Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. 1998 Mol. Cell. Biochem. pmid:9774182
Cox AD et al. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. 1992 Mol. Cell. Biol. pmid:1375323
Lagace TA et al. Caspase processing and nuclear export of CTP:phosphocholine cytidylyltransferase alpha during farnesol-induced apoptosis. 2002 Mol. Cell. Biol. pmid:12052891
McMahon LP et al. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. 2005 Mol. Endocrinol. pmid:15459249
Halaschek-Wiener J et al. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. 2000 Mol. Med. pmid:11055588
Funari SS et al. Farnesol and geranylgeraniol modulate the structural properties of phosphatidylethanolamine model membranes. 2005 Jul-Aug Mol. Membr. Biol. pmid:16154902
Colabardini AC et al. Involvement of the Aspergillus nidulans protein kinase C with farnesol tolerance is related to the unfolded protein response. 2010 Mol. Microbiol. pmid:21091509
Savoldi M et al. Farnesol induces the transcriptional accumulation of the Aspergillus nidulans Apoptosis-Inducing Factor (AIF)-like mitochondrial oxidoreductase. 2008 Mol. Microbiol. pmid:18681941
Bai C et al. Characterization of a hyperactive Cyr1 mutant reveals new regulatory mechanisms for cellular cAMP levels in Candida albicans. 2011 Mol. Microbiol. pmid:21992526
Davis-Hanna A et al. Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. 2008 Mol. Microbiol. pmid:18078440
Hogan DA et al. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. 2004 Mol. Microbiol. pmid:15554963
Cugini C et al. Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. 2007 Mol. Microbiol. pmid:17640272
Dichtl K et al. Farnesol misplaces tip-localized Rho proteins and inhibits cell wall integrity signalling in Aspergillus fumigatus. 2010 Mol. Microbiol. pmid:20398212
Semighini CP et al. Farnesol-induced apoptosis in Aspergillus nidulans reveals a possible mechanism for antagonistic interactions between fungi. 2006 Mol. Microbiol. pmid:16420349
Bandara HM et al. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro. 2016 Mol. Pharm. pmid:27383205
Zhang X et al. PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel. 2014 Mol. Pharm. pmid:24987803
Benford HL et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. 1999 Mol. Pharmacol. pmid:10385693
Maher M et al. Activation of TRPA1 by farnesyl thiosalicylic acid. 2008 Mol. Pharmacol. pmid:18171730

Table of Content